BMS and Pfizer reach settlement with Teva
Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).
The parties filed a stipulation and order of dismissal at the US District Court for the District of Delaware on Thursday, September 7. District Judge Leonard Stark signed the order the following day.
Teva had filed an ANDA to market a generic version of Eliquis (apixaban) drug, an anticoagulant used to prevent serious blood clots.
In 2007, BMS and Pfizer announced a worldwide collaboration to develop and commercialise apixaban.
Pfizer paid BMS $250 million as part of the apixaban agreement.
In response to the ANDA, BMS and Pfizer filed a lawsuit against Teva in April this year, alleging that the ANDA would infringe US patent number 9,326,945, called “Apixaban formulations”.
The parties have now settled the dispute, dismissing all claims and counterclaims without prejudice. Each party will pay their own costs and attorneys’ fees.
It stated that (below paragraphs) all claims and counterclaims have dismissed without prejudice, with each party to pay its own costs and attorneys’ fees.
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
Sign up for our latest webinar, Biotech patentability issues in Europe.
